Gregory F. Schimizzi, MD

Biosimilar Nonmedical Switching Must Never Undermine Patient Safety

June 29, 2018

While managing costs is extremely important to physicians and their patients, achieving and maintaining disease control without increasing the risk of complications or toxicities must remain the primary goal in the treatment of chronic inflammatory diseases.